Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging | 2022-04-11 | Press Releases

Ability to process more than 100 samples per week, with 1.6 times the lower limit of detection

SOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Nasdaq:LAB), Driven by Bold Purpose – unleash tools to accelerate breakthroughs in human health – today announced the launch of the Hyperion+™ Imaging System, the new standard in high-plex spatial imaging, delivering lower detection limits as well as sample capacity and lead time improved results.

The Hyperion™+ Imaging System provides researchers with an in-depth understanding of disease and treatment response, with the ability to stratify subjects by linking high-plex data to clinical study results. The system can process over 100 samples per week, operating at twice the speed of the current Hyperion imaging system, with a 1.6x lower detection limit. This allows for the detection of dark markers, an advantage that can be critical for low-expression markers often used in translational studies.

Results of a study using the Hyperion+ imaging system to improve understanding of the biology and pathophysiology of the tumor microenvironment in pancreatic invasive ductal adenocarcinoma (PDAC) will be presented today from 1:30 p.m. to 5:00 p.m. CDT at a poster session at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans (Summary 1709/6).

“Two critical challenges in realizing the full transformative potential of this remarkable technology are reducing the time required to answer key biological questions and detecting important biomarkers that are expressed at low levels,” ” said Michael Egholm, PhD, CEO and President of Standard BioTools. “The Hyperion+ Imaging System is designed to address these issues with a faster time-to-result and lower detection limit than the current Hyperion Imaging System. These capabilities are essential to quickly uncover important spatial relationships through high-plex spatial imaging of more than 40 markers simultaneously at subcellular resolution.”

“The new Hyperion+ imaging system enables researchers to gain deeper insights into molecules and pathways that can advance the medical community’s ability to diagnose, treat and mitigate the risk of serious health conditions,” said Egholm .

Key benefits of the Hyperion+ Imaging System include:

  • Superior phenotyping based on high-quality quantitative single-cell data from biomarkers using 25 to over 100 slides per week, generated without autofluorescence or multiple throughput-limiting staining and imaging cycles. This high-quality data helps clients make fast and confident decisions in translational research.
  • Up to 10x savings over immunohistochemistry using an efficient and simple stained image analysis workflow, unlike other complex cyclic immunofluorescence or digital profiling approaches.
  • The most proven high-plex proteomics approach for scanning eight to 40+ targets in a single run, with easy scaling to 100+ targets. This enables customers to optimize the evaluation of new immunotherapies by accurately phenotyping the tissue microenvironment to monitor disease progression, therapeutic response and drug activity.

“Developing safer and more effective cancer therapies and identifying patients most likely to benefit from immunotherapy requires a detailed understanding of protein expression at the single cell level and spatial interactions between cells in the tumor microenvironment,” said Bernd Bodenmiller, PhD, Professor in the Department of Quantitative Biomedicine at the University of Zurich and the Institute for Molecular Health Sciences at ETH Zurich.

“My research group was able to rapidly conduct extremely detailed phenotyping studies using the speed enhancements now available in the Hyperion+ imaging system, which give us unprecedented insight into how cells in the tumor microenvironment function and interact with each other and with the extracellular matrix,” said Bodenmiller. “This knowledge is the foundation for innovating the next generation of cancer diagnostics and therapies and improving outcomes for cancer patients.”

Standard BioTools will unveil the Hyperion+ Imaging System today at 10:15 a.m. CDT in exhibit booth 718 at AACR, with executives and technical experts available to answer questions. A video presentation on the Hyperion+ Imaging System will be released at 10:30 a.m. CDT. For those not attending the conference, the video can be viewed, starting at 8:00 a.m. PT todayto

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the performance, functionality and anticipated customer benefits of new Standard BioTools products and the benefits potential of research conducted using BioTools Standard Products and Technologies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from results currently anticipated, including, but not limited to, risks relating to interruptions or delays in the supply of components or materials for, or manufacture of, Standard BioTools products; potential product performance and quality issues; intellectual property risks; competition; uncertainties in contractual relationships; and reductions in research and development expenditures or changes in budget priorities by customers. Information about these additional risks and uncertainties and other information affecting Standard BioTools’ business and operating results are contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements, except as required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), formerly known as Fluidigm, is driven by a bold goal – unleash tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop drugs faster and better. As a leading solutions provider, the company delivers reliable, repeatable health and disease insights using its proprietary mass cytometry and microfluidics technologies, which help turn scientific discoveries into better ones. patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more about or join us on Twitter, Facebook, LinkedInand Youtube. Standard BioTools, the Standard BioTools logo, Hyperion and Hyperion+ are trademarks and/or registered trademarks of Standard BioTools Inc. or its subsidiaries in the United States and/or other countries. All other trademarks are the exclusive property of their respective owners. Standard BioTools products are provided for Use for research only. Not for use in diagnostic procedures.

Information available

Standard BioTools uses its website (, investor website (, company Twitter account (@fluidigm), Facebook page ( and the LinkedIn page ( as channels for the distribution of information about its products, its planned financial and other announcements, its participation in upcoming investor and industry conferences, and other matters. This information may be considered material information, and Standard BioTools may use these channels to comply with its disclosure obligations under the FD Regulations. Accordingly, investors should monitor Standard BioTools’ website and social media accounts in addition to monitoring its press releases, SEC filings, public conference calls and webcasts.


Marc Spearman

Standard biological tools

650 243 6621

[email protected]


Peter DeNardo

415 389 6400

[email protected]

main logo

Comments are closed.